RxDoctor Payments Data

Horacio Agueros, MD

Family Medicine · Austin, TXNPI 1477586618

Payments from drug & device makers

$941in general payments, 2019–2025

Across 53 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$288
  • Sanofi-aventis U.S. LLC$233
  • Astellas Pharma US Inc$161
  • Boehringer Ingelheim$79
  • Novo Nordisk$69
  • Amgen$31
  • plus $81 from 4 others

What the payments were for

  • Food & beverage$84189%
  • Education$10011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$941 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$17,245
Medicare patients
87
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$125,589
OzempicSemaglutide69$80,705
TradjentaLinagliptin34$41,904
JanuviaSitagliptin Phosphate32$32,981
MounjaroTirzepatide29$32,730
RybelsusSemaglutide20$29,344
JanumetSitagliptin Phos/Metformin Hcl15$24,805
TrulicityDulaglutide17$22,787
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$19,344
FarxigaDapagliflozin Propanediol15$19,236
EliquisApixaban16$17,646
GlyxambiEmpagliflozin/Linagliptin18$17,590
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$16,462
Soliqua 100-33Insulin Glargine/Lixisenatide19$15,640
Tresiba Flextouch U-100Insulin Degludec20$13,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$79$185,083142 claims
Novo NordiskOzempic, Rybelsus$69$110,04989 claims
Lilly USA, LLCMounjaro, Trulicity$288$55,51846 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$233$15,64019 claims
Astellas Pharma US IncMyrbetriq$161$13,41721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →